Nasdaq GlobeNewswire

Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae

Del

CINCINNATI, 2016-04-28 08:00 CEST (GLOBE NEWSWIRE) --

Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene Mycoplasma Direct assay features a simplified procedure compared to the existing illumigeneMycoplasma product. The new procedure will significantly expand Meridian’s customer base by eliminating the need for specialized techniques and training, as well as providing definitive results in less than one hour.

The launch of illumigene Mycoplasma Direct adds to the already robust illumigene menu that includes molecular tests for Group A Streptococcus, Pertussis, C. difficile, Chlamydia, Gonorrhea, HSV 1&2, Group B Streptococcus, and Malaria. All illumigene products are distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribution network.

Mike Shaughnessy, Executive Vice President and President of Meridian Global Diagnostics stated, “We are excited to improve upon the only CE-marked and FDA-cleared stand-alone molecular assay for Mycoplasma pneumoniae (illumigene Mycoplasma). By simplifying the procedure we are able to provide more customers with a superior diagnostic tool that will improve patient care. Due to the lack of cell wall in Mycoplasma, typical antibiotics like penicillin and cephalosporin are not effective, making rapid, targeted detection for appropriate treatment of the utmost importance.”

Often referred to as “walking pneumonia”, M. pneumoniae is associated with up to 40% of community-acquired pneumonias and has been increasingly prevalent in the majority of data-reporting European countries. Infection occurs in both children and adults without geographical, gender or climate-related restrictions. M. pneumoniae is most often associated with atypical pneumonia, presenting with symptoms that include headache, malaise, fever and sore throat accompanied by dry, paroxysmal cough.

illumigene Mycoplasma Direct is effective immediately as symptoms appear, by amplifying the specific DNA for the detection of active Mycoplasma pneumoniae infection. This represents a significant advancement in improving healthcare diagnoses and outcomes by providing a fast and definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner. M. pneumoniae bacterial culture lacks sensitivity and is often impractical for patient management as the organism may take as long as up to six weeks to culture. The ability to avoid treating patients empirically will reduce the administration of broad spectrum antibiotics and the likelihood of antimicrobial resistance.

The illumigene Mycoplasma test utilizes throat swabs and provides highly sensitive and specific results. It requires no expensive capital equipment or service contract. The test relies upon a simple procedure that takes less than two minutes of hands on time. The simplicity of this technology, along with its cost efficiency and small footprint, makes this innovative test ideal for enabling a more rapid diagnosis; providing earlier identification of outbreaks and prevention of secondary cases though implementation of control measures.

About Meridian Bioscience, Inc
Meridian is a fully integrated life science company that develops markets and distributes a broad range of innovative diagnostic tests, purified reagents and related products and offers biopharmaceutical enabling technologies in more than 60 countries worldwide. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. For more information please visit www.meridianbioscience.com.

         Contact: 513.271.3700
         John A. Kraeutler, Chief Executive Officer

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CORRECTING and REPLACING -- PRESS ALERT & INVITATION: Arbitrade to Hold a Press Conference on June 28th From Bermuda - Its New Global Headquarters23.6.2018 14:00Pressemelding

NEW YORK, June 23, 2018 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by Arbitrade, please note that the correct date of the event is Thursday, June 28, 2018 at 8:00 a.m. EDT. The corrected release follows: This is an invitation to all media following Arbitrade and/or covering the cryptocurrency markets. You are invited to join Arbitrade's Chairman, Len Schutzman, and management who will discuss their progress toward establishing Arbitrade as a world-class cryptocurrency exchange and coin company. They will also discuss their move and incorporation into Bermuda, one of the world's best regulated jurisdictions and a platform from which Arbitrade will reach out to several international markets. It will be a lively discussion that will also include details of the many economic and social advantages and new jobs that companies, like Arbitrade, will bring to countries in which they settle and do business around the world. Details of how to access the pr

15th Consecutive Nasdaq Closing Cross Sets Record for Number of Shares Traded During 2018 Russell US Indexes Reconstitution22.6.2018 23:19Pressemelding

NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) today announced the Nasdaq Closing Cross had a record day as it was used for the 15th consecutive year to rebalance Nasdaq-listed securities in the entire family of Russell U.S. Indexes, part of leading global index provider FTSE Russell, during their annual reconstitution. A record 1.188 billion shares representing $39.26 billion were executed in the Closing Cross in 0.935 seconds across some 2,591 Nasdaq-listed stocks. This compares to 2017, when Nasdaq executed 972 million shares representing $28.9 billion executed in 0.861 seconds across 2,499 Nasdaq-listed stocks. "Today, we saw a record-breaking performance for the Nasdaq Closing Cross, which benefits issuers and investors alike with transparent and efficient price discovery," said Tom Wittman, Head of Global Equities and Executive Vice President of Global Trading and Market Services at Nasdaq. "The rebalance is an important event to ensure that the Russell U.S. ind

PRESS ALERT & INVITATION: Arbitrade to Hold a Press Conference on June 28th From Bermuda - Its New Global Headquarters22.6.2018 22:29Pressemelding

NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- This is an invitation to all media following Arbitrade and/or covering the cryptocurrency markets. You are invited to join Arbitrade's Chairman, Len Schutzman, and management who will discuss their progress toward establishing Arbitrade as a world-class cryptocurrency exchange and coin company. They will also discuss their move and incorporation into Bermuda, one of the world's best regulated jurisdictions and a platform from which Arbitrade will reach out to several international markets. It will be a lively discussion that will also include details of the many economic and social advantages and new jobs that companies, like Arbitrade, will bring to countries in which they settle and do business around the world. Details of how to access the press briefing webcast are as follows: Please register now for the upcoming Arbitrade Conference Call: Date: Wednesday, June 27, 2018 Time: 8:00 a.m. EST We recommend that you connect to the meeting at l

Northland Power's Hai Long Offshore Wind Project Awarded Additional 744 Megawatts in Taiwan Auction22.6.2018 14:15Pressemelding

TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that the Taiwan Bureau of Energy ("BOE") has awarded 232 megawatts ("MW") to the Hai Long 2 offshore wind farm ("Hai Long 2") and 512 MW to the Hai Long 3 offshore wind farm ("Hai Long 3") under Taiwan's offshore wind auction program. These awards are separate from and in addition to the 300 MW in 2024 that Hai Long 2 was allocated by the Taiwan BOE on April 30, 2018 under Taiwan's Feed-in-Tariff ("FIT") program. Northland and its partner Yushan Energy Co. Ltd. ("Yushan Energy") own 60% and 40%, respectively, of Hai Long 2 and Hai Long 3. This is another significant step for Northland in Taiwan, with a second and third project progressing to connect to Taiwan's grid in 2025, subject to securing 20-year power purchase agreements. Taken together with the FIT award, the Hai Long 2 and Hai Long 3 offshore wind farms now total 1,044 MW of offshore wind capacity in Taiwan. Northland is bui

Williams Scotsman to Acquire ModSpace22.6.2018 13:09Pressemelding

Creates an industry-leading specialty rental services provider with over $1 billion of combined revenue and over 160,000 rental units across North America Leverages, and further strengthens, Williams Scotsman's scalable operating platform to capture an estimated $60 million of cost synergies Combines the best of both companies' go-to-market strategies, benefiting our customers and accelerating the expansion of Williams Scotsman's turnkey "Ready To Work" solutions across a broader asset base and enhanced branch network Total enterprise value of approximately $1.1 billion represents 6.6x ModSpace's Adjusted EBITDA for the twelve month period ended March 31, 2018, inclusive of forecast cost synergies and the expected value of acquired tax attributes1 ,2 BALTIMORE, June 22, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman") the leading specialty rental services provider of innovative modular space and portable storage solutions across North America, today anno

Mash named as one of the Fintech 5022.6.2018 12:36Pressemelding

At an event held on Wednesday June 20th at the Silicon Valley Bank in London, UK, Mash was selected from over 1800 companies to the FinTech50 2018 list, joining FinTech giants like N26, Monzo, Raisin and Revolut on the list of Europe’s hottest FinTech companies. James Hickson, Group CEO of Mash commented, “This has been a transformational year for Mash and our momentum continues. The FinTech50 is the Oscars of our industry and as such, the competition for a place was incredibly high - only 14 new companies made it to the list with Mash being selected from over 1800 nominations. To be recognized as one of Europe’s leading Fintech companies is an incredible honor and a reflection of our dedicated team and our go forward ambition to be a major player in Europe. We extend an enormous thank you to the award committee for their support and our team for their incredible efforts” Tommi Lindfors, Chairman and founder of Mash Group, was pleased with the recognition: “The Fintech50 list recognize

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom